Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166

Morgan, 2011, Epithelial ovarian cancer, J Natl Compr Canc Netw, 9, 82, 10.6004/jnccn.2011.0008

Abulafia, 1997, Angiogenesis in primary and metastatic epithelial ovarian cancer, Am J Obstet Gynecol, 177, 541, 10.1016/S0002-9378(97)70143-1

Perren, 2011, A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799

Burger, 2013, Independent radiologic review of the gynecologic oncology group study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer, Gynecol Oncol, 131, 21, 10.1016/j.ygyno.2013.07.100

Burger, 2014, Risk factors for GI adverse events in phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A gynecologic oncology group study, J Clin Oncol, 32, 1210, 10.1200/JCO.2013.53.6524

Guiu, 2010, Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer, Gut, 59, 341, 10.1136/gut.2009.188946

Teoh, 2011, Antiangiogenic therapies in epithelial ovarian cancer, Cancer Control, 18, 31, 10.1177/107327481101800105

Slaughter, 2014, Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer, Gynecol Oncol, 133, 11, 10.1016/j.ygyno.2014.01.031

Leader, 2003, Automated lung segmentation in X-ray computed tomography: Development and evaluation of a heuristic threshold-based scheme, Acad Radiol, 10, 1224, 10.1016/S1076-6332(03)00380-5

Yoshizumi, 1999, Abdominal fat: Standardized technique for measurement at CT, Radiology, 211, 283, 10.1148/radiology.211.1.r99ap15283

Nemoto, 2014, Development of automatic visceral fat volume calculation software for CT volume data, J Obes, 2014, 495084, 10.1155/2014/495084

Liou, 2006, Fully automated large-scale assessment of visceral and subcutaneous abdominal adipose tissue by magnetic resonance imaging, Int J Obes (Lond), 30, 844, 10.1038/sj.ijo.0803216

Concato, 1993, The risk of determining risk with multivariable models, Ann Intern Med, 118, 201, 10.7326/0003-4819-118-3-199302010-00009

Draper, 1998, Applied Regression Analysis, 115, 10.1002/9781118625590.ch4

Hosmer, 2013, Applied Logistic Regression, 35, 10.1002/9781118548387.ch2

Li, 2006, Reduction of bias and variance for evaluation of computer-aided diagnostic schemes, Med Phys, 33, 868, 10.1118/1.2179750

Cox, 1984, Analysis of Survival Data, 91

Simkens, 2011, Influence of body mass index on outcomes in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy, Eur J Cancer, 47, 2560, 10.1016/j.ejca.2011.06.038

Ladoire, 2011, Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents, Oncologist, 16, 71, 10.1634/theoncologist.2010-0227

Steffens, 2011, Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?, Oncologist, 16, 1565, 10.1634/theoncologist.2011-0213

Miyazawe-Hoshimoto, 2003, Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects, Diabetologia, 46, 1483, 10.1007/s00125-003-1221-6

Modesitt, 2012, Not all fat is equal: Differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose and endometrium of obese women with and without endometrial cancer, Int J Gynecol Cancer, 22, 732, 10.1097/IGC.0b013e3182510496

Dusserre, 2000, Differences in mRNA expression of the proteins secreted by adipocytes in human subcutaneous and visceral adipose tissues, Biochem Biophys Acta, 1500, 88